Zevra Therapeutics (ZVRA) Gains from Sales and Divestitures (2024)
Zevra Therapeutics (ZVRA) reported Gains from Sales and Divestitures of $765945.0 for Q4 2024.
Zevra Therapeutics (ZVRA) Gains from Sales and Divestitures (2024) Analysis & Trends
Zevra Therapeutics has reported Gains from Sales and Divestitures for 1 years, with the latest figure at $765945.0 in Q4 2024.
- For the quarter ending Q4 2024, Gains from Sales and Divestitures changed N/A year-over-year to $765945.0; the trailing twelve-month figure through Dec 2024 stood at $765945.0 (changed N/A YoY), and the FY2024 full-year result was $765945.0, changed N/A from the prior year.
- Gains from Sales and Divestitures for Q4 2024 stood at $765945.0.
- The five-year high for Gains from Sales and Divestitures was $765945.0 in Q4 2024, with the low at $765945.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Zevra Therapeutics | 787.90 Mn | 587.28 Mn | 34.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 765,945.00 |
| Dec 31, 2024 | 765,945.00 |